At the 2025 ODAC Dermatology Conference, we had the privilege of hearing from Dr. Adam Friedman, a renowned expert in dermatology and the chair of the department of dermatology at the George Washington, as he shared his expert insights into the evolving landscape of off-label treatments for challenging dermatologic conditions. Dr. Friedman addressed the complexities of managing conditions such as … Continue reading "Off-Label Treatments for Papulosquamous Diseases: Insights from Dr. Adam Friedman"
Colchicine, a microtubule polymerization inhibitor, was first described for use in treating joint pain and swelling in ancient Egypt and has since become a mainstay in the medical management of gout. Beyond its indicated uses, it has numerous off-label dermatologic applications, particularly for neutrophilic and autoimmune conditions. As a potent anti-inflammatory, colchicine requires careful lab … 
The February 2025 issue of the Journal of Drugs in Dermatology brings a fresh wave of clinical insights and innovative research to the dermatology community. This edition highlights new perspectives on minoxidil adherence, groundbreaking findings in keloid and hypertrophic scar risk factors, and expert consensus on deucravacitinib for plaque psoriasis.
Readers will also discover updates on non- …